In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran (Q43171890)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 May 2012

Language	Label	Description	Also known as
English	In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran	scientific article published on 16 May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

influenza vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Seyyed Mahmoud Ebrahimi

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Mehran Dabaghian

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Majid Tebianian

3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Mohammad Hossein Zabeh Jazi

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

language of work or name

0 references

publication date

16 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

430

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

63-72

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Removal of endotoxin from protein solutions by phase separation using Triton X-114

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Regulation of pH by the M2 protein of influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Influenza A viruses: why focusing on M2e-based universal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Study of infection with an Iranian field-isolated H9N2 avian influenza virus in vaccinated and unvaccinated Japanese quail

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Time lines of infection and disease in human influenza: a review of volunteer challenge studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Characterization of immunity induced by M2e of influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Fusion expression of major antigenic segment of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

A "universal" human influenza A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Viral ion channels: structure and function.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Modified M2 proteins produce heterotypic immunity against influenza A virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Viral shedding and clinical illness in naturally acquired influenza virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Avian influenza virus (H5N1): a threat to human health.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

A universal influenza A vaccine based on the extracellular domain of the M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Lethal H5N1 influenza viruses escape host anti-viral cytokine responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Pharmacokinetic and tissue distribution mechanism of mouse recombinant heat shock protein 70 in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

Novel features of the respiratory tract T-cell response to influenza virus infection: lung T cells increase expression of gamma interferon mRNA in vivo and maintain high levels of mRNA expression for interleukin-5 (IL-5) and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

based on heuristic

inferred from DOI database lookup

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.04.015

7 January 2021

based on heuristic

inferred from DOI database lookup

A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1093/OXFORDJOURNALS.AJE.A118408

Identifiers

10.1016/J.VIROL.2012.04.015

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43171890&oldid=1982837765"